Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios

[1]  G. Dehmer,et al.  Drug-eluting coronary artery stents. , 2009, American family physician.

[2]  C. M. Agrawal,et al.  Evaluation of poly(L-lactic acid) as a material for intravascular polymeric stents. , 1992, Biomaterials.

[3]  V. Kocka,et al.  Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’ , 2014, European heart journal.

[4]  Joanna J Wykrzykowska,et al.  3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. , 2010, JACC. Cardiovascular interventions.

[5]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[6]  P. Serruys,et al.  Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial , 2011, The Lancet.

[7]  P. Serruys,et al.  Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Me , 2011, JACC. Cardiovascular interventions.

[8]  P. Erne,et al.  The Road to Bioabsorbable Stents: Reaching Clinical Reality? , 2006, CardioVascular and Interventional Radiology.

[9]  S. Achenbach,et al.  Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold , 2014, Clinical Research in Cardiology.

[10]  P. Serruys,et al.  ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease c , 2012, American heart journal.

[11]  R. Whitbourn,et al.  Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. , 2011, JACC. Cardiovascular interventions.

[12]  R. Whitbourn,et al.  Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial , 2012, Heart.

[13]  P W Serruys,et al.  Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. , 1988, Circulation.

[14]  J. Tanigawa,et al.  Retrograde approach to coronary chronic total occlusions: preliminary single European centre experience. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[15]  Patrick W Serruys,et al.  Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. , 2011, JACC. Cardiovascular interventions.

[16]  Bernard Chevalier,et al.  Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.

[17]  Patrick W Serruys,et al.  The ABSORB bioresorbable vascular scaffold: an evolution or revolution in interventional cardiology? , 2012, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[18]  Bernard Chevalier,et al.  Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.

[19]  A. Grüntzig.  TRANSLUMINAL DILATATION OF CORONARY-ARTERY STENOSIS , 1978, The Lancet.

[20]  P. Dobrin,et al.  Influence of initial length on length-tension relationship of vascular smooth muscle. , 1973, The American journal of physiology.

[21]  P. Serruys,et al.  Bioresorbable polymeric vascular scaffolds: a cautionary tale. , 2011, Circulation. Cardiovascular interventions.

[22]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[23]  John A Ormiston,et al.  First‐in‐human implantation of a fully bioabsorbable drug‐eluting stent: The BVS poly‐L‐lactic acid everolimus‐eluting coronary stent , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[24]  Patrick W Serruys,et al.  Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  Bernard Chevalier,et al.  European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[26]  Masataka Nakano,et al.  The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.

[27]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[28]  Hani Jneid,et al.  2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c , 2011, Journal of the American College of Cardiology.

[29]  Orchard Tj.  Letter: Mobile coronary care. , 1974 .

[30]  S. Lobodzinski,et al.  Bioabsorbable coronary stents. , 2008, Cardiology journal.

[31]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.

[32]  Raimund Erbel,et al.  Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial , 2013, The Lancet.

[33]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[34]  Raimund Erbel,et al.  Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial , 2007, The Lancet.

[35]  David B Matchar,et al.  Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.

[36]  Bernard Chevalier,et al.  Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[37]  T. Lüscher,et al.  Acute thrombosis of bioabsorbable scaffold in a patient with acute coronary syndrome. , 2013, European heart journal.

[38]  T. Münzel,et al.  Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.